Benjamin P. Levy, MD, medical director, Thoracic Oncology, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

More agents have been approved in the field for patients with 

 mutations within the past year, Levy explains, such as gefitinib. Prior to such approvals, treatment choices included erlotinib and afatinib. The combination of erlotinib plus bevacizumab is also being investigated in an ongoing US study.

There are also third-generation TKIs previously used for resistant disease that are now being studied in the frontline setting, Levy says.

View more from the 2015 NY Lung Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

PER® New York Lung Cancer Symposium

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer. 


Dr. Levy on EGFR TKIs in Lung Cancer